Abstract Monocyte chemotactic protein-1 (MCP-1) belongs to the CC chemokine superfamily and plays a critical role in the recruitment and activation of leukocytes during acute inflammation. We hypothesize that MCP-1 is also an important chemokine that regulates the recruitment and activation of bone cells required for skeletal repair and remodeling. We used the ulnar stress fracture (SFx) model, which allows investigation of focal remodeling with a known time course and precise anatomical location. SFx were created in the right ulna of female Wistar rats using cyclic end loading. Unloaded animals were used as a control. Rats were killed 4 h and 1, 4, 7, and 14 days after loading (n = 10/group); RNA was extracted and converted to cDNA for quantitative PCR analysis using TaqMan gene expression assays. Four hours after loading, MCP-1 gene expression was increased *30-fold (P \ 0.001), remained elevated at 24 h (*12-fold, P \ 0.001), then declined by day 14. Relative to the contralateral limb, expression of the receptors CCR1 and CCR2 increased over the 14 days, being significant by 4 days for CCR1 and 14 days for CCR2 (P \ 0.05). Other inflammation-related chemokines (RANTES, MIP1a) were not increased at these early time points. Using in situ hybridization and immunohistochemistry in separate animal groups (n = 5/group, control, days 1, 4, 7), MCP-1 mRNA and protein were localized in periosteal osteoblasts associated with woven bone formation at the fracture exit point but not in osteocytes adjacent to the SFx. These data support an important role for MCP-1 in the early phase of SFx repair and activated remodeling.
Introduction
Bone remodeling occurs throughout life and is necessary to maintain the integrity of cortical and cancellous bone. It turns over aged bone tissue, removes skeletal microdamage, reorganizes fracture callus, and repairs stress fractures (SFx) [1] . This highly coordinated process ensures that skeletal integrity is maintained. Conversely, dysregulated bone remodeling impairs bone quality and is central to many diseases of bone, such as osteoporosis and Paget disease. Basic multicellular units (BMUs) are formed during remodeling and consist of osteoclasts, osteoblasts, and their precursors. Following an activation event, remodeling progresses by resorption of bone matrix followed by new bone formation until a new bone structural unit is completed. Bone marrow and bone are anatomically contiguous and form a functional unit, whereby the bone marrow niche provides sources of hematopoietic and nonhematopoietic stem cells that are precursors for bone and immune cells. Fundamental mechanisms that initiate remodeling events, like recruitment of cells to the BMU, are not well understood; but chemokines are strong contenders for regulating cell attraction to a BMU during remodeling activation.
Cells of the immune system secrete chemokines and cytokines. Chemokines are low-molecular weight proteins (8) (9) (10) that are important for host defense systems and normal tissue maintenance. They are divided into four subfamilies (CC, CXC, C, CX 3 C), based on the spacing of the first two, conserved, cysteine residues. The role of chemokines in the immune system has been extensively studied [2, 3] , but knowledge of their interactions in bone cell biology remains rudimentary. Under pathological conditions, osteoblasts increase production of CCL20 (macrophage inflammatory protein 3 alpha, MIP3a) compared to those from normal tissues [4] . CCL20 also induces osteoclast differentiation by increasing the number of osteoclast progenitors and assists cell fusion via the production of matrix metalloproteinase-9 (MMP-9) [4] . It is also upregulated following SFx production [5] . Stromal differentiation factor 1a (SDF-1a or CXCL12) increases osteoclast resorption, the size of resorption pits, and the number and elevated expression of RANKL, cathepsin K, MMP-9, and TRAP when cultured with peripheral bloodderived osteoclast precursors [6] . We also observed a modest increase in gene expression for SDF-1 following SFx initiation in vivo [1] . Similarly, macrophage inflammatory protein 1a (MIP1a or CCL3) acts directly on osteoclast progenitors to enhance osteoclast formation [7, 8] . Many cytokines and chemokines also regulate osteoblast [9, 10] and osteoclast function [11, 12] . In addition, gene array studies demonstrate that chemokine expression associated with angiogenesis, e.g., CXCL10 and -13, increases soon after SFx in the rat ulna [5] .
Monocyte chemotactic protein-1 (MCP-1 or CCL2) is a member of the CC chemokine superfamily that plays a critical role in the recruitment and activation of leukocytes during acute inflammation [1, 13] . In addition, MCP-1 is found at the site of tooth eruption, a feature consistent with a role in osteoclast biology [14] . Importantly, MCP-1 is induced by RANKL and promotes osteoclast fusion into multinuclear cells [15] . Moreover, following treatment of rats with parathyroid hormone (PTH), MCP-1 was the most induced gene on array analysis, being induced by an order of magnitude greater than the next three candidate genes identified [16] . In the anabolic regime, PTH caused MCP-1 induction to increase over time until it was [200-fold after 14 days of treatment. While numerous chemokines provide regulation of both chemotaxis and osteoclast differentiation during inflammatory bone remodeling, we hypothesize that MCP-1 is specifically regulated in skeletal repair and physiological remodeling.
We previously observed an upregulation of cytokines such as IL-6 during early phases of SFx healing, and this peak of expression coincided with the initiation of woven bone formation, suggesting IL-6 involvement in the signaling of new bone formation. Oncostatin M (OSM), another cytokine that stimulates bone resorption [17] , is also expressed by osteoblasts and acts locally to promote bone formation and resorption in vitro [18] . Our aim was to determine if OSM is regulated coincidently with MCP-1 in vivo in skeletal repair and remodeling.
We have optimized a rat model of SFx that presents an approach to examine focal bone remodeling with a known time course and precise anatomical location [1, 19] . This offers an opportunity to explore cellular signaling of bone remodeling in vivo, in particular the involvement of chemokines and cytokines during skeletal repair. Our specific aim was to investigate the expression of chemokines in the CC family (MCP-1, RANTES, MIP1a) and a cytokine involved in bone formation (OSM) and their receptors (CCR1, CCR2, OSMr) during initiation and progression of remodeling that repairs the SFx in the rat ulna.
Materials and Methods

Experimental Animals
A total of 98 female Wistar rats aged 17-18 weeks with an average weight of 322 ± 3 g were purchased from The University of Queensland Biological Resources Unit, housed in pairs, and allowed ad libitum feeding and free cage activity between loading sessions. Experiments were approved by the Griffith University Animal Ethics Committee and followed NHMRC guidelines for the care and use of laboratory animals. For gene expression studies, a total of five experimental groups from 4 h to 14 days postloading were examined (4 h and days 1, 4, 7, and 14; n = 10 per group except n = 8 for 4 h). An unloaded control group (ULC) provided baseline control values. For in situ hybridization (ISH) and immunohistochemistry (IHC), separate experimental groups were used (ULC and days 1, 4, and 7) with n = 5 per group.
Ulna Loading to Create SFx
The loading regime followed our previously published protocol [1] . Briefly, animals were anesthetized with isoflourane and their forelimbs were positioned in a customdesigned mechanical device. SFx was generated on the ulna by axial compressive cyclic loading with an applied load of 17-30 N and a 2-Hz cycle frequency. LabChart v7.1 (AD Instruments, Colorado Springs, CO) was used to monitor the displacement curve, and the loading was manually stopped when a 10 % increase in displacement value was reached. The average total number of loading cycles for the experiment was 10,645 ± 447 (mean ± SD). A single subcutaneous injection of an opioid analgesic (buprenorphine, 0.05 mg/kg) was used following each loading session. No sign of behavioral changes was observed in experimental animals after loading.
ULC and contralateral left ulnae of loaded rats were used as negative controls. At each time point after loading rats were killed using CO 2 asphyxiation; the right (loaded) and left ulnae were dissected; and soft tissue was removed (except for periosteum), snap-frozen in liquid nitrogen, and stored at -80°C until use. At death, blood was collected via cardiac puncture into a 3-mL BD Vacutainer Ò blood collection tube (BD Biosciences, San Jose, CA). The tubes were inverted several times, incubated for 30 min at room temperature, and centrifuged at 1,3009g for 10 min to allow phase separation. The clear serum was collected and stored at -20°C until use.
RNA Extraction
Total RNA was extracted from the bone using a Trizol protocol, as previously described [1] . Briefly, the epiphyses were dissected and the ulnar diaphyses were ground into fine powder in liquid nitrogen using a mortar and pestle. The ground bone powder was homogenized with 1 mL of Trizol and spun at 12,0009g for 10 min at 4°C. The supernatant was collected and mixed with 200 lL of chloroform and spun at 12,0009g for 15 min at 4°C to allow phase separation. The clear aqueous phase was collected and the RNA precipitated using glycogen and isopropanol overnight at -20°C. RNA was extracted again using phenol chloroform to remove impurities, and the pellet was resuspended in 11 lL of RNAse DNase-free water (Invitrogen, Carlsbad, CA). RNA was quantified using Nanodrop1000 (Thermo Scientific, Wilmington, DE) to determine yield and purity. RNA yield (mean ± SD) was 326 ± 28 ng/lL for the right ulna and 322 ± 28 ng/lL for the left ulna.
Quantitative Real-Time PCR RNA was treated with DNase I (Promega, Sydney, Australia) following the manufacturer's protocol to remove genomic DNA contamination. RNA was converted to cDNA using ImProm-II reverse transcriptase (Promega) and oligo dT primers. Taqman primers were used to detect the target genes (Table 1) . Quantitative real-time PCR was used to detect the expression of chemokines and cytokine using the BioRad (Gladesville, Australia) CFX96 real-time PCR detection system. The PCR cycling conditions were 95°C for 10 min to activate the Taq polymerase, followed by 40 cycles of annealing and extension step at 95°C for 15 s and 58°C for 70 s. The mRNA transcript level for each gene was normalized and expressed relative to the average expression of the HPRT and GAPDH housekeeping genes.
Serum ELISA MCP1 in serum was detected using a commercially available BD OptEIA TM Rat MCP-1 ELISA set (BD Bioscience). The ELISA was performed following the manufacturer's protocols. Briefly, a 96-well plate was coated with capture antibody at 4°C overnight. The plate was aspirated and washed with phosphate-buffered saline (PBS)/0.05 % Tween and blocked with 10 % fetal calf serum/PBS at room temperature for 1 h. The plate was aspirated and washed, and the standard or serum (diluted 1:100) was added to the corresponding well and incubated at room temperature for 2 h. The plate was aspirated and washed, followed by addition of working detector (detection Ab ? streptavidin-horseradish peroxidase) and incubated for 1 h at room temperature. The plate was aspirated and washed, followed by addition of 3,3 0 ,5,5 0 -tetramethylbenzidine substrate solution to each well and incubation for 15 min. The reaction was stopped by addition of 2 M H 2 SO 4 , and the absorbance was measured at 450 nm using a plate reader.
Riboprobe Synthesis cDNA plasmid templates were generated using PCR to amplify MCP-1 sequences from rat bone cDNA using specific primers (forward 5 0 -CAGGTCTCTGTCACGCTT CT-3 0 , reverse 5 0 -AGTATTCATGGAAGGGAATAG-3 0 ). PCR products were gel-extracted and purified using commercial kits (Promega) and ligated into the multiple cloning sites of pGEM-T Easy vector (Promega). The plasmid vector sequence was confirmed by DNA sequencing (DNA Sequencing Facility, Griffith University). Sense and antisense RNA probes were synthesized using T7 and SP6 DNA-dependent RNA polymerase promoters that are adjacent to each end of the multiple cloning sites of the plasmid. After linearization of the template DNA using SacI and SacII restriction enzymes (New England Biolabs, Ipswich, MA), riboprobe synthesis reaction consisted of digoxigenin (DIG)-UTP (Roche, Castle Hill, Australia), reaction buffers, placental RNAse inhibitor, and the appropriate RNA polymerase (Roche). The labeling conditions followed the manufacturer's instructions. The labeled probe was treated with DNase I and purified using ethanol precipitation. The RNA probe integrity was characterized by gel electrophoresis, and concentration was quantified by a Nanodrop spectrometer (Thermo, Scoresby, Australia). The RNA probe was stored at -80°C until use.
In Situ Hybridization (ISH)
Paraffin sections were dewaxed through three changes of xylene and descending concentrations of ethanol. After dewaxing, the tissue was first treated with 0.2 M HCL for 20 min to eliminate endogenous alkaline phosphatase activity, followed by digestion with 5 lg/mL of proteinase K [in 100 mM Tris-HCL (pH 8.0), 50 mM EDTA) for 30 min at 37°C. Proteinase K activity was stopped by soaking sections in 2 mg/mL glycine made up in PBS for 5 min and washed with two changes of PBS. The section was then refixed in 4 % paraformaldehyde made up in PBS for 15 min at room temperature, rinsed in several changes of PBS and diethylpyrocarbonate-treated water. Sections were equilibrated in hybridization buffer (50 % formamide, 59 SSC, 2 % block reagent, 0.02 % SDS, 0.1 % Nlauroylsarcosine) for 1 h at 42°C in a humidified chamber and incubated with 1 ng/lL of the respective RNA probe at 42°C overnight. Sections were sequentially washed with descending concentrations of standard saline citrate (29, 19 , 0.19) for 15 min each (two changes) and rinsed briefly with 100 mM Tris (pH 7.5), 150 mM NaCl. Sections were incubated with the same buffer but containing 1 % blocking reagent for 30 min in a humidified chamber at room temperature, followed by 1-h room-temperature incubation with 1:500 dilution of anti-DIG-alkaline phosphatase (DIG-AP) antibody (made up in buffer 2). Sections were washed with two changes of buffer 1 for 15 min each and equilibrated in buffer 3 (100 mM Tris-HCL, 100 mM NaCl, 50 mM MgCl 2 , pH 9.5) for 3 min. For color development, sections were incubated with 250 lL of color substrate solution (45 lL 75 mg/mL NBT solution ? 35 lL 50 mg/mL x-phosphate made up in 10 mL solution 3, filter-sterilized) at room temperature. Color development was monitored every hour, and the reaction was stopped by incubating the sections with buffer 4 (10 mM Tris-HCL, 1 mM EDTA, pH 8.0). Stained sections were mounted in 0.2 % propyl gallate in PBS/50 % glycerol. Controls included the sense probe or omission of probes and anti-DIG-AP antibody sections.
Immunohistochemistry (IHC)
Anti-rat MCP-1 primary antibody and its respective isotype control were purchased commercially (Abcam, Cambridge, MA). Sections were deparaffinized using xylene and rehydrated through descending concentrations of ethanol. Antigen retrieval was performed using microwave heating in 10 mM EDTA buffer, and the sections were washed with Tris-buffered saline (TBS) for 5 min following antigen retrieval. Nonspecific protein binding was eliminated by incubating sections with 10 % fetal calf serum (made up in TBS) for 1 h at room temperature. Specimens were then incubated at 4°C overnight with the primary antibody diluted to 5 lg/mL made up in TBS. Normal rabbit IgG (5 lg/mL; Santa Cruz Biotechnology, Santa Cruz, CA) was used as the isotype control. The following day, sections were washed with TBS for 5 min, followed by elimination of endogenous peroxidase activity by blocking with 3 % H 2 O 2 for 30 min at room temperature. Sections were washed with TBS and incubated with 2 lg/mL of goat anti rabbit biotinylated IgG secondary antibodies (made up in TBS) for 30 min at room temperature, followed by a 5-min wash with TBS. Sections were incubated with streptavidinhorseradish peroxidase complex (Dakocytomation, Bella Vista, Australia) diluted 1:300 in TBS for 30 min, followed by 5-min washes with TBS. Streptavidin-horseradish peroxidase activity was detected by incubating sections with liquid diaminobenzidine chromogen (Dakocytomation) for a predetermined time, followed by washing for 5 min in deionized water. Sections were counterstained with Mayer's hematoxylin for 1 min, followed by rinsing in running tap water for 5 min. Sections were then dehydrated overnight and mounted in Cytoseal permanent mounting medium (ProSciTech, Thuringowa, Australia).
Microscopy
Sections were examined using bright field optics on an Olympus (Center Valley, PA) BX60 microscope. Classification of cells was based on morphology, and all immunostained slides were counterstained with hematoxylin to allow visual identification of the cells. Sections for ISH were not counterstained. Sections were examined from each time point from days 1, 4, and 7; but cell-based morphometry was not quantified because woven bone confounded the surface observations and osteocytes did not express the MCP-1 protein or mRNA.
Statistical Analysis
Differences among groups in gene expression were analyzed using one-way ANOVA with post hoc analysis of between-group differences using Fisher's protected least significant difference test (SPSS 17.0; SPSS, Inc., Chicago, IL). Significance was determined at P \ 0.05. Fold differences between the loaded (right) and the opposite unloaded (left) ulnae were determined for each time point, and paired t tests were performed to determine significant differences. For all tests, the significance level was P \ 0.05 or greater.
Results
Gene Expression in Unloaded Ulna
To determine basal expression of our target genes in bone, mRNA expression was examined in ulnae from unloaded animals (Fig. 1) . The expression of each gene varied quite markedly in the tissue, with MIP1a, OSM, and OSMr expressed at the lowest level. There were no significant differences between MCP-1 mRNA expression with RANTES, CCR1, and CCR2 (P [ 0.05). However, the mRNA level of MCP-1 was 164 times higher than that of MIP1a (P \ 0.001), 36 times that of OSM (P \ 0.001), and about ninefold higher than that of OSMr (P \ 0.01). Nonetheless, the target genes under investigation were expressed in bone tissue.
Gene Expression in SFx Ulna
Following loading, MCP-1 was the only chemokine that significantly increased its gene expression compared to the ULC (Table 2 ; Fig. 2) . At 4 h, MCP-1 gene expression was *30-fold higher (P \ 0.001) than ULC; and this had declined to 12-fold by day 1 (or 24 h) (P \ 0.001). By day 4, MCP-1 expression dropped to a threefold increase, with the expression maintained at this level until day 14. For 2 weeks postloading, MCP-1 expression remained elevated compared to ULC (Fig. 2a) . Both the chemokine receptors, CCR1 and CCR2, showed a marginal increase, with mRNA expression of CCR1 peaking by day 4 (2.4-fold, P \ 0.05) and CCR2 by day 14 (fourfold, P \ 0.05) compared to ULC. CCR2 also showed significant increases at each time point compared to the contralateral ulna (Table 2) .
Compared to ULC, MIP1a, RANTES, OSM, and OSMr showed no significant increase in expression. But compared to unloaded contralateral limbs (Table 2) , OSMr showed a small 2.3-fold induction (P \ 0.0002). At day 4 RANTES showed a small 1.7-fold increase (P \ 0.01), and at day 7 MIP1a increased by 4.2-fold (P \ 0.002).
MCP-1 Serum Level
To determine if the observed MCP-1 mRNA peak was tissue-specific or had a significant effect on the systemic level of MCP-1 in the rat, serum MCP-1 protein was measured by ELISA. Similar to the gene expression data, the serum protein level of MCP-1 peaked by day 1 (1.5-fold, P \ 0.001) and dropped to basal level by day 4.
In Situ Hybridization and Immunohistochemistry
Based on the gene expression study, MCP-1 was examined using ISH and IHC analyses. MCP-1 in the rat ulna was localized to determine which cell types express this chemokine around the SFx region. Day 7 postloading was chosen for Fig. 3 (ISH) because woven bone formation reaches its maximum by that time and coincides with the appearance of BMUs at this site. For IHC (Fig. 4) , images from days 1, 4, and 7 are included to demonstrate protein expression in bone cells at these time points. Moderate staining of MCP-1 mRNA was localized in periosteal osteoblasts from day 1 and osteoblasts within the woven bone at day 7. Osteocytes adjacent to, or distant from, the SFx were negative for MCP-1. Cells within the bone marrow cavity also showed mRNA expression for MCP-1 (Fig. 3) . IHC localization of MCP-1 protein showed a similar pattern of expression as its mRNA (Fig. 4) . MCP-1 protein was predominantly localized in periosteal osteoblasts (Fig. 4a) , osteoblasts in the woven bone (Fig. 4b, c) , and some of the bone marrow cells (Fig. 4f) . Other cell types that showed positive staining for MCP-1 protein are stromal cells at the periosteal surface and chondrocytes at the growth plate (data not shown).
Discussion
The role of chemokines in immune regulation has been extensively studied but less so their regulation of activated bone remodeling. Under baseline physiological conditions, gene expression for the chemokines MCP-1, RANTES, MIP1a, and their receptors was detected in bone to varying degrees. Following initiation of SFx, MCP-1 was specifically regulated compared to the other chemokines examined, with increased gene expression during the early stage of remodeling activation ( Fig. 2; Table 2 ). This was further Fig. 2 Gene expression of chemokine MCP-1 and the receptors CCR1 and CCR2 and serum protein level of MCP-1 after initiation of SFx. a Relative to the ULC, an early increase in MCP-1 gene expression occurred 4 h postloading, which declined markedly by day 4 but remained significantly greater than the contralateral ulna to day 14. Gene expression of both CCR1 (b) and CCR2 (c) marginally increased over the time course compared to the ULC. CCR1 was significantly greater than ULC at day 7 and increased to day 14.
Relative to ULC, CCR2 peaked at day 14 after loading (c) but was significantly greater in loaded ulnae relative to the contralateral side from 4 h. Serum protein levels of MCP-1 followed a similar trend for its gene expression, peaking by day 1 and decreased to basal levels by day 4 (d) after SFx initiation. Transcript level is relative to the housekeeping genes HPRT and GAPDH. Left ulnae were used as contralateral controls. ULC unloaded control. ***P \ 0.001, **P \ 0.01, *P \ 0.05 compared to ULC; (parentheses show pairwise differences between left and right ulnae, P \ 0.05)
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cytokine OSM showed no consistent increase during 14 days following SFx. Combined with the significant increase in MCP-1 expression associated with PTH treatment in rats [16] , these data point to an important role for MCP-1 in the activation phase of SFx healing and bone remodeling. In the anabolic protocol, MCP-1 exhibited the greatest increase in gene expression on array analysis following PTH treatment [16] . Several other lines of evidence demonstrate involvement of the CC chemokine subfamily (MCP-1, RANTES, MIP1a) in pathological bone conditions such as multiple myeloma [7] , rheumatoid arthritis, and osteoarthritis [20, 21] . Increased activity of osteoclasts is a common phenotype of these bone conditions that lead to osteolysis. Unlike these immune-associated bone conditions, PTH treatment and SFx are not associated with an inflammatory cascade. However, they do share common signaling pathways, such as those sharing the gp-130 coreceptor subunit, such as IL-6 and IL-11 that regulate RANK-L/OPG signaling [1, 22] and signaling via PGE 2 stimulation of cAMP [23, 24] .
Both woven bone formation and bone remodeling require angiogenesis to support the bone cell activity. The increase in angiogenic chemokines observed following SFx [5] is highly consistent with the increase in MCP1 observed here because both chemokines attract the cells required to support tissue repair and remodeling. Localization of MCP-1 was observed in periosteal osteoblasts at the SFx site (Fig. 3) , supporting a hypothesis that osteoblastic expression of MCP-1 is involved in osteoclast recruitment and differentiation at the stage of osteoclastogenesis. That process is initiated simultaneously with the increase in woven bone formation that stabilizes the exit point of the SFx. It is difficult to separate the signaling events that regulate these biological processes. Nonetheless, the activation of the periosteum and the increase in bone formation activity provide a rich source of osteoblastic cells capable of signaling via MCP1 expression. Collectively, our data implicate MCP-1 as an important molecule for signaling the activation phase of remodeling. A limitation of this conclusion is that we have not specifically tested the effect of MCP1 inhibition.
Osteoblastic cells are critical partners in the recruitment of osteoclast progenitors from the circulation to remodeling sites, and several chemokines regulate this process. For example, SDF1 (CXCL12), CCL9 (MIP-1c), and CCL1 play a role in osteoclast attraction, fusion, and/or bone resorption [25] [26] [27] . Our group previously reported that MCP-1 also promotes human osteoclast fusion [15, 28] . In those experiments, cells treated with MCP-1, but without RANKL, formed TRAP ? multinuclear cells that closely resembled osteoclasts but were unable to resorb bone [15] . GM-CSF overrides the osteoclast differentiation pathway, leading to dendritic cells even in the presence of RANKL. In that process, GM-CSF suppressed the RANKL-mediated induction of MCP-1. However, adding back MCP-1 resulted in the reversal of GM-CSF repression of osteoclast differentiation, suggesting that MCP-1 has a number of different potent effects on osteoclast differentiation [15] . We demonstrated that SFx heals by direct remodeling, by which BMUs migrate along the SFx line to repair the damage [1] . In this model, increases in gene and protein expression of target molecules can be unequivocally related to the remodeling event initiated by SFx. This is because rat cortical bone does not undergo secondary remodeling under normal conditions and changes in molecular events can be precisely linked to osteoclastogenesis and origination of a BMU. Unlike other chemokines we have investigated ( Table 2 [1]), MCP-1 was significantly increased within 4 h of the activation phase of remodeling, suggesting a key role in the recruitment of precursor cells to the site of remodeling and bone formation.
In the anabolic application of ulnar loading, in which SFx was not generated, microarray analysis identified a group of chemokines, including MCP-1, that were upregulated within 4 h of loading [29] . These were downregulated later in the time course of adaptation when matrix formation was initiated. Although the SFx protocol engenders a remodeling response, it also initiates early woven bone formation at the fracture exit point to stabilize the SFx [1] . In our model, both chemokine receptors CCR1 and CCR2 were moderately increased up to day 14 after the initiation of SFx, whereas Mantila Roosa et al. [29] supported a downregulation of these genes during the matrix formation phase of adaptation (up to 5 weeks after loading). The discrepancy between these data likely relates to the activation of remodeling in the SFx model and the fact that loading of the right ulna exerts a systemic effect on the left contralateral unloaded ulna in the SFx protocol [1, 30] . Mantila Roosa et al. [29] used only contralateral controls, making interpretation of data difficult but reinforcing the importance of the ULC, as we have done.
We localized MCP-1 mRNA and protein in osteoblasts within the woven bone and stromal cells adjacent to the SFx site. From our experience with this model, osteoclasts are observed 1 week after SFx, with the appearance of BMU migrating along the SFx line by 2 weeks. Localization of MCP-1 at a site destined for remodeling is Fig. 4 Localization of MCP-1 protein by IHC in bone tissue adjacent to the SFx exit point 1, 4, and 7 days after mechanical loading. MCP-1 protein is localized in osteoblastic cells in the periosteum (Ps) 1 day following loading (a, small arrow) and in the woven bone at the fracture exit point at 4 (b) and 7 (c) days after loading. Osteocytes adjacent to, and distant from, the SFx were negative for MCP1 staining (e); but bone marrow cells were positive (f). Isotype controls (d) were negative for nonspecific staining. Images counterstained with hematoxylin. Thick arrow indicates original periosteal margin. Scale bar 50 lM. WoB woven bone, Ot osteocyte consistent with our hypothesis that chemokines are activated to recruit osteoclasts and their precursor cells to the site of remodeling. We also know that inflammatory cells are absent at the SFx site [1] , supporting our observations that osteoblasts are the main cell type to synthesize MCP-1 protein during skeletal repair.
We have found OSM and OSMr to be expressed at a low level in unloaded rat ulnae compared to housekeeping genes (Fig. 1a) . Following SFx initiation, there was no significant increase in the mRNA expression of OSM and its receptor. Conversely, Mantila Roosa et al. [29] showed an upregulation at 4 h after adaptive mechanical loading. OSM induces osteoblast proliferation and collagen synthesis [31] and promotes bone formation [18] in vitro. During differentiation of primary murine osteoblasts, or Kusa4b10 cells, expression of OSM and its receptor increases as osteoblastic cells mature from days 7 to 14. The principal ''adaptive'' response to ulnar loading is new lamellar bone formation, in contradistinction to the SFx model in which woven bone formation and bone remodeling occur. OSM, therefore, appears to be more concerned with the regulation of bone matrix formation than early signaling of the BMU progenitors.
In conclusion, we identified that the chemokine MCP-1 is specifically regulated during the early phase of remodeling following SFx initiation. MCP-1 mRNA and protein were localized in osteoblasts adjacent to the SFx. Because MCP-1 is secreted by osteoblasts and its receptor CCR2 can be found in osteoclasts [28] , it is a strong candidate as an important signaling molecule attracting osteoclasts and its precursors to the site of bone remodeling.
